Published in Women's Health Weekly, April 14th, 2005
"Novavax has taken a series of necessary steps in 2004 to transition itself for long term growth and sustainability. These steps included the building of a talented organization, implementation of a strategy to capitalize on micellar nanoparticle (MNP) technology as a delivery system to a wide range of pharmaceuticals, and the commercialization of our first internally developed pharmaceutical product, ESTRASORB," said Nelson M. Sims, president and CEO, Novavax, Inc.
For the fourth quarter ended December 31, 2004, the company had a net loss of $10.3 million,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly